Skip to content

Advertisement

  • Research
  • Open Access

Coenzyme Q10 combined with trimetazidine in the prevention of contrast-induced nephropathy in patients with coronary heart disease complicated with renal dysfunction undergoing elective cardiac catheterization: a randomized control study and in vivo study

  • 1,
  • 1Email author,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
European Journal of Medical Research201823:23

https://doi.org/10.1186/s40001-018-0320-2

  • Received: 15 January 2018
  • Accepted: 24 April 2018
  • Published:

Abstract

Background

Contrast-induced nephropathy (CIN) is one of the common hospital-acquired acute renal failures. The purpose of this study was to investigate whether Coenzyme Q10 (CoQ10) and trimetazidine (TMZ) can prevent the occurrence of CIN after elective cardiac catheterization in patients with coronary artery disease complicated with renal dysfunction.

Methods

Consecutive coronary artery disease patients with renal insufficiency scheduled for coronary angiography were enrolled in randomized, paralleled, double-blind, controlled trial. The development of CIN was occurrence at the 48 or 72 h after the procedure. The changes of serum creatinine (SCr), eGFR, and Cys-C within 72 h after the procedure were measured and compared. In vivo contrast medium (CM)-induced acute kidney injury (AKI) animal model was established, and CoQ10 plus TMZ was orally administrated to evaluate its renal protective effect.

Results

150 patients with renal insufficiency were enrolled finally. CIN occurred in 21 (14.00%) of the 150 patients. 72 h after the procedure, the incidence of CIN was significantly lower in CoQ10 plus TMZ group compared with control group (6.67 vs. 21.3%, p = 0.01). No cardiac death occurred in this study. No side effects were observed after administration of CoQ10 and TMZ. In vivo test demonstrated that CoQ10 and TMZ could significantly reduce the concentration of blood urea nitrogen (BUN) and SCR induced by CM i.v. injection, as well as tubular pathological injuries. Meanwhile, CoQ10 and TMZ could significantly reduce the oxidation stress in kidneys from CM-AKI animals.

Conclusion

CoQ10 plus TMZ could decrease the incidence of CIN in patients with renal insufficiency undergoing elective cardiac catheterization, and their effect may be due to its strong anti-oxidation effect.

Keywords

  • Percutaneous coronary intervention
  • Contrast-induced nephropathy
  • Coenzyme Q10
  • Trimetazidine
  • Prevention
  • Animal model

Background

Percutaneous coronary intervention (PCI) is one of the most effective therapies for coronary heart disease. With the improvement of interventional technique of coronary artery in recent years, the number of percutaneous coronary intervention was increasing [13]. Treating complicated coronary artery disease, especially chronic occlusion disease (CTO), is not a difficult problem presently [4]. Contrast agents are often used in coronary interventions, especially a large number of contrast agents are used in complex coronary lesions and CTO. However, using of contrast agents in clinical coronary angiography and PCI treatment could cause acute renal impairment (AKI), especially for patients with pre-existing renal failure [5, 6].

Contrast-induced nephropathy (CIN) is one of the commonly acquired acute renal failures in hospital, which could cause higher mortality, higher treatment costs, and prolonged hospitalization [7, 8]. The clinical and basic research of CIN has become the hot spot currently. Hydration and maintenance of circulating volume are still the main measurement to prevent contrast nephropathy [9]. Clinical studies also showed that several drugs can prevent contrast nephropathy, including antioxidants (N-acetylcysteine, statins), diuretic (furosemide), and vasodilators (such as calcium antagonists, dopamine, fenoldopam) [10, 11]. However, the therapeutic effect of these drugs is uncertain, and still needs to be verified in larger clinical trials.

Studies have shown that reactive oxidative stress and oxygen species (ROS) play an important role in the apoptosis of renal tubular epithelial cells induced by contrast media [12]. As a strong antioxidant, Coenzyme Q10 (CoQ10) could alleviate oxidative stress-induced damage in cell and mitochondrial membrane. Several researches also demonstrate CoQ10 has cardiac protective effect for patients with coronary heart disease [13]. Trimetazidine (TMZ) hydrochloride could maintain the energy metabolism of cells under hypoxia or ischemia condition. It could increase coronary blood flow reserve and reduce the frequency of angina pectoris significantly in patients with coronary heart disease [14].

Based on their pharmacological effect of CoQ10 and TMZ, we hypothesize that CoQ10 and TMZ may reduce the risk of CIN. The purpose of this study was to investigate whether combination of CoQ10 and TMZ can prevent the occurrence of CIN after elective cardiac catheterization in patients with coronary artery disease complicated with renal insufficiency. After clinical trial, we established a contrast-induced acute kidney injury (CI-AKI) in rats, and CoQ10 and TMZ was administrated orally to assess their renal protective effect.

Methods

The study protocol was approved by the ethics committee of the second Hospital of Hebei Medical University. Informed consent was obtained on admission. The study was conducted in accordance with the Declaration of Helsinki. The study was registered in Chinese Clinical Trial Registry with the serial number, ChiCTR-INR-17010449.

Study population

This study was a randomized, paralleled, double-blind, controlled trial. From Jan 2016 to Aug 2017, 180 consecutive coronary artery disease (CAD) patients with renal insufficiency scheduled for coronary angiography (CAG) were enrolled in cardiology department, the second hospital of Hebei Medical University. The inclusion criteria were age ≥ 18 years, males or females, patients with coronary heart disease who would subsequently undergo elective cardiac catheterization and estimated glomerular filtration rate (eGFR) ≤ 60 mL/min/1.73 m2. Exclusion criteria: current Coenzyme Q10 and trimetazidine (TMZ) treatment; high-risk features warranting emergency coronary angiography (within 4 h); renal failure requiring dialysis; contrast agent exposure within the previous 7 days; left ventricular ejection fraction (LVEF) < 30%; administration of N-acetylcysteine within 48 h of the procedure and refusal of consent. The renal insufficiency was defined as an estimated glomerular filtration rate (eGFR) ≤ 60 mL/min/1.73 m2. The eGFR was calculated by serum creatinine (SCr) levels and the modification of diet in renal disease (MDRD) equation:
$${\text{eGFR }}\left( {{\text{mL}}/{ \hbox{min} }/1.73\,{\text{m}}^{2} } \right) = 186 \times {\text{SCr}}^{ - 1.154} \times {\text{age}}^{ - 0.203} \left( { \times 0.742\,{\text{for}}\,{\text{female}}\,{\text{subjects}}} \right).$$

Study protocol

Recruited patients were randomly assigned to CoQ10 [Eisai (china) Pharmaceutical Co. Ltd, Suzhou, China] plus TMZ [Servier (Tianjin) Pharmaceutical Co. Ltd, Tianjin, China] group or control group by a 1:1 ratio using computer-generated random numbers (Fig. 1). In CoQ10 plus TMZ group, both of CoQ10 and TMZ were administered 20 mg three times daily from 2 days before to 3 days after procedure. Control group were given same packaged placebo as the same method.
Fig. 1
Fig. 1

Flow diagram of the study. ECC elective cardiac catheterization, CIN contrast-induced nephropathy, MAE major adverse event

Coronary angiography and percutaneous coronary intervention (PCI) were performed by radial or femoral approach. The procedure was performed by the same medical team in both groups. The contrast agent (Ultravist 370, iodine 370 mg/mL, Schering Pharmaceutical Ltd., China) was used for all patients. All patients were treated with hydration as below: an intravenous infusion of 0.9% saline at a rate of 1 or 0.5 mL/kg/h (patients with LVEF < 40%) 4 h before and 20 h after elective coronary procedure.

During the PCI, An intravenous bolus of unfractionated heparin (70–100 U/kg) or bivalirudin (0.75 mg/kg injected intravenously as a load dose before PCI, continuous infusion of 1.75 mg/kg/h for no more than 4 h) was given for anticoagulation. The platelet glycoprotein IIb/IIIa inhibitors (GPI) were administered according to condition of coronary lesions. Moreover, aspirin (100 mg/day) and clopidogrel (75 mg/day) were routinely administrated to prevent platelet aggregation before and after the procedure. If the patient received PCI, dual antiplatelet therapy continued for at least 12 months unless severe bleeding complications occurred. Before randomization, and at 48, 72 h after contrast agent exposure, blood samples were collected to measure the levels of SCr with the Hitachi 7600 automated biochemistry analyzer (Hitachi, Ltd., Tokyo, Japan) and Cystatin-C (Cys-C) with the Mindray BS-800 automated biochemistry analyzer (Shenzhen Mindray Bio-Medical Electronics Co., Ltd, Shenzhen, China).

Study endpoints

The primary endpoint was development of CIN, 48 or 72 h after the procedure. CIN defined as 25% relative increase in SCr from baseline or absolute increase of 44 μmol/L (0.5 mg/dL) after exposure to contrast medium. The secondary endpoints were (1) the changes of SCr, eGFR, and Cys-C within 72 h after the procedure; (2) major adverse events occurring within 30 days after contrast medium exposure were recorded, including all-cause death, myocardial infarction, renal failure requiring dialysis, stroke, upper gastrointestinal bleeding, and worsening heart failure which was defined as a deteriorated NYHA (New York Heart Association) functional class. All patients had a follow-up in out-patient clinic or contacted by telephone at 30 days.

Induction of CI-AKI and experimental treatment

Male Sprague–Dawley rats (180–200 g) were purchased from Hei Bei medical university (Shijiazhuang, Hebei, China). The rats were kept in individual cages under controlled conditions at 20–24 °C on a 12:12-h light/dark cycle and had free access to tap water and a standard laboratory diet. All experimental protocols were approved by the Committee on the Ethics of Animal Experiments of the School of Medicine, Hebei medical University (HM-20170111) and were in compliance with the Guide for the Care and Use of Laboratory Animals by the National Academy Press.

CI-AKI was induced by using a previously reported method [15]. In brief, rats were deprived of water for 72 h and then given 10 mg/kg furosemide (Harvest Pharmaceutical Co., Shanghai, China) by intramuscular injection. After 20 min, a non-ionic, low-osmolar contrast media (CM, Omnipaque, 350 mg I/mL; GE Healthcare, Shanghai, China) was administered by intravenous injection (10 mL/kg) via the tail vein over the course of 5 min.

Forty-five rats were randomly allocated to the following five groups (N = 8 per group): (1) control group (dehydration + furosemide, without CM administration); (2) CI-AKI group; (3) CI-AKI + CoQ10 and TMZ group (10 mg/kg for both drugs); (4) CI-AKI + CoQ10 and TMZ group (20 mg/kg for both drugs). Baseline blood samples were collected from the jugular vein under light ether anesthesia at the end of acclimatization period, and the serum was separated from the whole blood. CoQ10 and TMZ were administered by oral gavage once daily for three consecutive days prior to CM injection and once at 4 h after CM injection. The rats were allowed to recover for 24 h after the CM injection and then sacrificed by light ethyl ether anesthesia. The final blood samples were collected through the jugular vein. After harvesting the kidneys, the left kidney was stored at − 80 °C for biochemical analysis, and the right kidney was fixed in 10% formalin for histopathological evaluation.

Biochemical test for renal Function

Blood urea nitrogen (BUN) and serum creatinine (SCr) concentration was determined using an automatic biochemical analyzer (Hitachi 7600, Japan) at the central clinical laboratory of second hospital of Hebei Medical University.

Histopathological analysis of kidney tissues

Kidney tissue was fixed in 10% neutral buffered formalin, embedded in paraffin, cut into 3 μm sections, and stained with hematoxylin and eosin (H&E). Histopathological analysis was performed in a blinded manner using a light microscope (Olympus, Japan). Ten high-magnification (× 200) fields of the cortex and outer stripe of the outer medulla were randomly selected for semiquantitative analysis.

The renal lesions were graded according to following criterions: Tubular necrosis and proteinaceous casts were graded as follows: 0 = no damage, 1 = mild (unicellular, patchy isolated damage), 2 = moderate (< 25% damage), 3 = severe (25–50% damage), or 4 = very severe (> 50% damage).

Measurement of oxidative stress markers in vivo and in vitro

Kidneys were homogenized in PBS using a Tissuelyser-38 (Jingxin industrial development co. Ltd, Shanghai, China) and then centrifuged at 3000g for 10 min. The pellet was discarded and protein content was measured in supernatant using the bicinchoninic acid (BCA) assay (Applygen Technologies Inc. Beijing, China). Supernatant aliquots were used to determine the oxidative markers, including nitric oxide (NO), glutathione (GSH), lipid peroxidation (LPO), activity of superoxide dismutase (SOD), and catalase (CAT). The test procedure was followed as specifications of each commercial kits (Nanjing Jiancheng biotechnology, Nanjing, China).

Statistical analysis

According to previous research, it is speculated that the incidence of CIN after the procedure was 20% in control group, and we hypothesized the CoQ10 plus TMZ group could reduce the incidence of CIN to 5%. In view of the above, at least 73 patients each group were required for the power of the test set at 0.8 and statistical level (2-sided) at 0.05. The continuous variables were expressed as means with standard deviation for normally distributed variables while as median with interquartile range for non-normally distributed variables. The categorical variables were presented as percentage. Continuous variables were compared using the Student t test for normally distributed value and the Mann–Whitney U test for non-normally distributed. Proportions were compared using the Chi-square test, and if the expected frequency was < 5, the Fisher exact test would be applied. Analysis of variance (ANOVA) was used to compare the difference of SCr, eGFR, and Cys-C levels before and after the procedure in each group. Multivariate logistic regression analysis was used to explore the possible factors associated with the incidence of CIN. For the in vivo animal study, all measurement data were presented as mean ± standard error (SEM), Comparison of the same parameters among all groups was done using one-way analysis of variance (ANOVA), and the difference between pairs of means was tested post hoc with Tukey’s test. p < 0.05 was considered statistically significant. All calculations were analyzed with the SPSS statistical software (version 17.0, SPSS Inc., Chicago, IL).

Results

According to the inclusion criteria, a total of 180 patients were enrolled initially. 30 patients were excluded, who declined to participate (5), whose previous contrast media exposure was within 7 days (8), who received coenzyme Q10 or (and) TMZ within 1 week (5), had severe comorbidities (8), and had renal failure requiring dialysis (4). Finally, a total of 150 patients with renal insufficiency were enrolled and were randomly divided into the CoQ10 plus TMZ group (n = 75) and control group (n = 75) (Fig. 1).

Baseline characteristics

Baseline characteristics of the patients were similar in the two groups (Table 1). There were no significant differences between the two groups about age, gender, body mass index (BMI), hypertension, diabetes mellitus, hyperlipidemia, smoking, LVEF, laboratory results, medications, used of bivalirudin, and GPI. There were 39 patients (52.00%) in the CoQ10 plus TMZ group and 36 patients (48.00%) in the control group which underwent PCI (p = 0.430). The volume of the contrast medium used during the coronary procedure was 136.40 ± 68.57 mL in the CoQ10 plus TMZ group and 130.13 ± 63.79 mL in the control group (p = 0.563).
Table 1

Baseline clinical characteristics of the patients

Variables

CoQ10 + TMZ group (n = 75)

Control group (n = 75)

p value

Age (years)

61.75 ± 9.15

63.52 ± 7.88

0.205

Female, n (%)

34 (45.33)

33 (44.00)

0.870

BMI (kg/m2)

26.30 ± 4.06

25.43 ± 2.85

0.131

Hypertension, n (%)

32 (42.67)

35 (46.67)

0.622

Diabetes mellitus, n (%)

31 (41.33)

34 (45.33)

0.621

Hyperlipidemia, n (%)

29 (38.67)

26 (34.67)

0.611

Smoking, n (%)

39 (52.00)

41 (54.67)

0.743

LVEF (%)

56.18 ± 6.53

54.62 ± 5.68

0.121

AMI, n (%)

13 (17.33)

10 (13.33)

0.479

Previous myocardial infarction n (%)

11 (14.67)

8 (20.67)

0.461

Laboratory results

 Hemoglobin (g/L)

125.01 ± 9.28

126.25 ± 9.72

0.426

 Glycosylated hemoglobin (%)

6.08 ± 0.88

6.26 ± 1.00

0.229

 Low-density lipoprotein cholesterol (mg/dL)

118.79 ± 18.45

117.75 ± 21.39

0.750

Medications, n (%)

 β-blocker

52 (69.33)

49 (65.33)

0.601

 ACEI/ARB

42 (56.00)

38 (50.67)

0.513

 Statins

67 (89.33)

71 (94.67)

0.229

 Diuretics

6 (8.00)

8 (10.67)

0.575

 Nitrate

40 (53.33)

46 (61.33)

0.322

 Calcium-channel blocker

32 (42.67)

38 (50.67)

0.326

 Proton pump inhibitors

20 (26.67)

16 (21.33)

0.444

 PCI, n (%)

39 (52.00)

36 (48.00)

0.624

 Use of bivalirudin, n (%)

26 (34.67)

21 (28.00)

0.379

 Use of GPI, n (%)

15 (20.00)

16 (21.33)

0.840

 Volume of CM (mL)

136.40 ± 68.57

130.13 ± 63.79

0.563

 CM ≥ 160 mL, n (%)

35 (46.67)

30 (40.00)

0.410

 Hydration volume (mL)

1754.40 ± 358.41

1716.32 ± 238.30

0.445

BMI Body mass index, AMI acute myocardial infarction, LVEF left ventricular ejection fraction, ACEI angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blockers, PCI percutaneous coronary intervention, GPI platelet glycoprotein IIb/IIIa inhibitors, CM contrast medium

The changes of renal function parameters and the incidence of CIN

The change levels of renal function parameters (SCr, eGFR, and Cys-C) were compared between the two groups (Table 2). There were no significant differences of SCr (118.18 ± 17.27 vs. 119.38 ± 14.81 μmol/L, p = 0.647), eGFR (51.28 ± 5.03 vs. 50.36 ± 4.15 mL/min/1.73 m2, p = 0.223), and Cys-C (1.51 ± 0.26 vs. 1.53 ± 0.20 mg/L, p = 0.503) on baseline between the CoQ10 plus TMZ group and control group. The levels of SCr and Cys-C increased at 48 h and declined at 72 h after procedure in both groups. Significant rise was observed in SCr and Cys-C levels at 48 and 72 h (p < 0.05) in control group compared with the baseline; Simultaneously, CoQ10 plus TMZ group only increased significantly in 48 h (p < 0.05). CoQ10 plus TMZ group tended to have a lower SCr and Cys-C levels than control group at 48 and 72 h after the procedure (all p < 0.05). The eGFR decreased significantly after the procedure in both groups, with the lowest value occurring at 48 h and then beginning to recover at 72 h. Compared with the control group, CoQ10 plus TMZ group tended to have a higher eGFR levels at 48 and 72 h after the procedure (46.30 ± 5.69 vs. 43.14 ± 5.81 mL/min/1.73 m2, p = 0.001; 50.70 ± 5.57 vs. 48.50 ± 5.24 mL/min/1.73 m2, p = 0.014).
Table 2

Changes of SCr, eGFR, and Cystatin-C, incidence of CIN

Variables

CoQ10 + TMZ group (n = 75)

Control group (n = 75)

p value

SCr (μmol/L)

 Baseline

118.18 ± 17.27

119.38 ± 14.81

0.647

 48 h after exposure

129.86 ± 21.75*

139.52 ± 20.21*

0.005

 72 h after exposure

118.97 ± 16.82

125.06 ± 15.11*

0.021

eGFR (mL/min/1.73 m2)

 Baseline

51.28 ± 5.03

50.36 ± 4.15

0.223

 48 h after exposure

46.30 ± 5.69*

43.14 ± 5.81*

0.001

 72 h after exposure

50.70 ± 5.57

48.50 ± 5.24*

0.014

Cystatin-C (mg/L)

 Baseline

1.51 ± 0.26

1.53 ± 0.20

0.503

 48 h after exposure

1.95 ± 0.43*

2.13 ± 0.35*

0.006

 72 h after exposure

1.55 ± 0.27

1.64 ± 0.21*

0.016

 Incidence of CIN, n (%)

5 (6.67)

16 (21.3)

0.010

SCr serum creatinine, eGFR estimated glomerular filtration rate, CIN contrast-induced nephropathy

* p < 0.05 compared with baseline

Overall, CIN occurred in 21 (14.00%) of the 150 patients. Within 72 h after the procedure, the incidence of CIN was significantly lower in CoQ10 plus TMZ group compared with control group (6.67 vs. 21.3%, p = 0.01).

Predictors of CIN by multiple logistic regression analysis

Multiple logistic regression analysis identified administration of CoQ10 plus TMZ as strong predictor of decreased risk of CIN (OR 0.252, 95% CI 0.082–0.774, p = 0.016). In addition, the results showed that the volume of contrast medium ≥ 160 mL (OR 5.570 95% CI 1.693–18.327, p = 0.005) and eGFR ≤ 45 mL/min/1.73 m2 (OR 3.010, 95% CI 1.058–8.556, p = 0.039) were independent predictors of CIN after coronary procedure (Table 3).
Table 3

Predictors of CIN by multivariate logistic analysis

Variables

OR

95% CI

p value

CoQ10 + TMZ

0.252

0.082–0.774

0.016

Sex

0.761

0.221–2.623

0.665

Age > 65

2.119

0.696–6.457

0.186

LVEF (%)

1.075

0.976–1.185

0.143

BMI

1.046

0.856–1.278

0.661

Diabetes

1.111

0.369–3.348

0.851

Hemoglobin

0.967

0.906–1.032

0.308

Contrast volume ≥ 160 mL

5.570

1.693–18.327

0.005

eGFR ≤ 45 mL/min/1.73 m2

3.010

1.058–8.556

0.039

CIN Contrast-induced nephropathy, eGFR estimated glomerular filtration rate

Clinical endpoints

One-month clinical follow-up was obtained in 148 of 150 patients (98.7%). The incidence of major adverse events has no significant difference between the two groups (6.76% vs. 8.1%, p = 0.754). There were 2 cases of worsening heart failure, 1 case stroke, 1 case upper gastrointestinal bleeding, and 1 case developed clinical renal failure occurred in the CoQ10 plus TMZ group after contrast exposure. In control group, there were 3 cases of worsening heart failure, 1 case myocardial infarctions, and 2 cases needed hemodialysis. None of the patients incurred cardiac death in this study. After administration of CoQ10 and TMZ, no side effects were observed.

CoQ10 and TMZ reduces renal dysfunction in rat with CM-induced renal injury

To investigate the effects of CoQ10 and TMZ on cisplatin-induced renal dysfunction, the serum levels of BUN and creatinine in rat were measured 24 h after CM injection. CM challenge elevated serum BUN and creatinine levels to 57.1 ± 5.67 and 0.63 ± 0.06 mg/dL, respectively, which was significantly higher than the normal control (26.3 ± 0.82 and 0.38 ± 0.07 mg/dL, respectively; Table 4). The CoQ10 and TMZ treatment significantly decreased BUN and creatinine levels compared to CM model control in a dose-dependent manner (Table 4).
Table 4

Blood urea nitrogen and serum creatinine at the post-treatment with the CoQ10 and TMZ in CM-induced AKI model

Groups

sham

CM

CM + CoQ10 and TMZ (10 mg/kg)

CM + CoQ10 and TMZ (20 mg/kg)

N

8

8

8

8

BUN (mg/dL)

26.3 ± 0.82

57.1 ± 5.67#

44.3 ± 4.38*

33.1 ± 3.21**

Scr (mg/dL)

0.38 ± 0.07

0.63 ± 0.06#

0.51 ± 0.09*

0.43 ± 0.05*

# p < 0.05, compared with sham control; * p < 0.05, ** p < 0.01, compared with CM model group

CoQ10 and TMZ reduced the oxidation in the CM-induced kidney tissues

As shown in Table 5, CM challenge caused significantly higher oxidative stress in the kidney tissues, which led to lower level of GSH and higher production of LPO, as well as decrease in antioxidant enzyme activities, such as SOD and Catalase. In the current study, CoQ10 and TMZ administration significantly ameliorated the oxidative stress in the CM-challenged kidney tissues by increasing the GSH level, SOD and catalase activities, while decreasing the LPO contents.
Table 5

Effect of CoQ10 and TMZ on oxidative biomarkers in CM-induced acute kidney injury

Groups

Sham control

CM

CM + CoQ10 and TMZ (10 mg/kg)

CM + CoQ10 and TMZ (20 mg/kg)

N

8

8

8

8

GSH (mmol/g tissue)

9.18 ± 1.21

2.69 ± 0.14#

5.47 ± 0.10*

6.42 ± 0.39*

MDA (nmol/g tissue)

21.5 ± 2.12

61.1 ± 2.34

45.6 ± 2.47*

30.9 ± 3.41**

Catalase (U/mg protien)

10.50 ± 0.68

4.42 ± 0.37#

6.69 ± 0.52

8.27 ± 0.30**

SOD (U/mg protein)

14.42 ± 0.48

7.36 ± 1.53#

10.49 ± 0.54*

12.55 ± 0.76*

#p < 0.05, compared with sham control; * p < 0.05, ** p < 0.01, compared with CM model group

CoQ10 and TMZ ameliorate the renal tubular impairment on pathological analysis

H&E staining for each kidney sections was performed to investigate the effect of CoQ10 and TMZ on cisplatin-induced renal tubular damage under light microscopy (×200 magnification). Serious tubular injuries were evident in the cisplatin-treated group. The main pathological characteristics included atrophy and degeneration of epithelial cells, hyaline materials and cast formation in the tubular lumen, and apoptosis and necrosis of tubular cells. After treatment with CoQ10 and TMZ, the damage was limited to mild necrosis of the tubular epithelial cells, slight epithelial swelling, and less cast formation was visible (Fig. 2a). Treatment with CoQ10 and TMZ significantly reduced the tubular necrosis score dose dependently compared to the score from CM-treated mice (Fig. 2b).
Fig. 2
Fig. 2

Effect of CoQ10 plus TMZ on contrast medium-affected renal tissues of rats by light microscopic examination (PAS). a Representative figures for each group. CM group had severe tubular damage with acute tubular necrosis, wide tubular epithelial vacuolation, and apoptotic tubular epithelium, while CoQ10 plus TMZ could reduce this pathological injuries. b Renal injury score. Each renal injury score value represents the mean of eight rats. All the pictures were taken under ×200 magnification

Discussions

This study indicates that receiving CoQ10 plus TMZ treatment before procedure could reduce the incidence of CIN for the patients with renal insufficiency undergoing elective cardiac catheterization. In addition, we evaluated risk factors in these patients for CIN development and observed that the volume of contrast medium and decreased eGFR were independent correlates of CIN. Moreover, we found that administration of CoQ10 plus TMZ was an independent protective factor against CIN by multiple Logistic regression analysis. This may provide us with a new strategy for the prevention and treatment of CIN.

CIN is an iatrogenic renal injury that follows the contrast medium exposure, which developed in 48–72 h. It could cause transient increase in SCr [16, 17]. Currently, despite prevention strategies advances, CIN remains responsible for approximately 10% of all hospital-acquired acute kidney injury [18, 19]. Moreover, patients developing CIN are at a high risk of both a further deterioration of kidney function and an adverse clinical outcome following CAG or PCI [19].

At present, the pathophysiology of CIN is still not very clear—two possible mechanisms may be involved: (1) the direct cytotoxicity of contrast media (CM) to renal medulla, which injures vascular endothelial cells and renal tubular, leads to production of reactive oxygen species (ROS), reduces production of nitric oxide (NO), and finally causes vasoconstriction [20]; (2) The high viscosity and high permeability of CM results in slowing flow of renal medullary blood, which eventually leads to renal medulla ischemia [21]. Hypoxia, vasoconstriction, and cytotoxicity are the major adverse effects of contrast media. The direct toxicity of contrast media to renal tubular epithelial cells and the caused apoptosis have been confirmed by many clinical trials and animal experiments [22]. Reactive oxygen species (ROS) and oxidative stress play an important role in the apoptosis of renal tubular epithelial cells induced by contrast media.

Coenzyme Q10 (CoQ10) is a lipid-soluble benzoquinone and has 10 isoprenyl units in its side chain. It is a very important component of the mitochondrial respiratory chain for adenosine triphosphate synthesis. Besides, CoQ10 is also an intracellular antioxidant that protects mitochondrial membrane protein, the membrane phospholipids, and low-density lipoprotein cholesterol (LDL-c) from free radical-induced oxidative damage [23]. Literature has shown that CoQ10 protects cardiovascular by reducing oxidative stress and reducing low-density lipoprotein (LDL), thereby reducing the risk of coronary artery disease [24].

Trimetazidine hydrochloride (TMZ) is an anti-myocardial ischemia drug. It can improve the cardiac function and increase the exercise tolerance in patients with ischemic cardiomyopathy. Researches have shown that TMZ has cell protective effects on anti-apoptosis of ischemia, reperfusion of myocardial cell, and anti-oxidation; it also can restore mitochondrial membrane stability, reduce Ca2+ ion-induced mitochondrial damage, and restore glutathione peroxidase level [25, 26]. In addition, TMZ can improve the utilization rate of lactic acid, decrease ketogenesis in cells, improve the lipid metabolism, and inhibit the reduction of effective circulating blood volume and renal insufficiency caused by acidosis [27, 28].

Few studies focused on the preventive effects of CoQ10 and TMZ on CIN. As far as we know, this study might be the first one to demonstrate that the combination therapy of CoQ10 and TMZ can reduce the incidence of CIN in patients with renal insufficiency undergoing elective cardiac catheterization. Although Onbasili [29] and Shehata [30] have demonstrated that TMZ could reduce the acute kidney injury caused by nephrotoxic drugs and reduce the incidence of CIN, there is still controversy about the value of TMZ in the prevention of CIN. In the current study, we used Chinese population to perform a two-blind clinical trial, and confirm their efficiency.

With the aim to further confirm renal protective effect of CoQ10 and TMZ on CIN, in vivo animal experiment study was performed. Renal function test demonstrated that CoQ10 and TMZ could significantly reduce the BUN and SCR induced by CM injection, as well as attenuating tubular injury by pathological analysis. Oxidation assay suggests that CoQ10 and TMZ could significantly reduce the LPO, and increase the GSH and enzyme activity of SOD and CAT. All these results support our clinical trial results that CoQ10 and TMZ could ameliorate the CIN due to their anti-oxidation effect.

The exact mechanism of CoQ10 combined TMZ into prevention of CIN remains unclear. The most certain is that the combination of CoQ10 and TMZ has a strong anti-oxidation effect, and oxidative stress is one of the important pathogenesis of CIN. CoQ10 and TMZ attenuate oxidative stress and protect blood endothelial cells via activating AMPK and ERK pathways, or Akt/eNOS signaling pathways [25, 31, 32]. All these studies support that combination of CoQ10 and TMZ may have preventive effects on CIN.

There are some limitations and shortcomings in this study. First, it is a single-center study with small data samples, which may weaken the statistical power of the conclusions; Second, this study did not evaluate the preventive effect of CoQ10 and TMZ on CIN separately, and therefore further study is still needed in the future to explore the prevention of CoQ10 or TMZ alone on the CIN and their comparison to N-acetylcysteine, which has clear clinical curative effect.

Conclusions

In conclusion, we demonstrated that oral CoQ10 plus TMZ could decrease the incidence of CIN in patients with renal insufficiency undergoing elective cardiac catheterization. The combination of CoQ10 and TMZ observed in this study suggests the therapeutic potential of the two drugs on prevention of CIN.

Declarations

Authors’ contributions

FC is in charge of manuscript writing and data analysis; JL and XY are in charge of data collecting; BX is in charge of animal experiment, YJ and JZ are in charge of pathological study. FL is in charge of design of whole study. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

The data and material are available if required for academic purpose.

Consent for publication

All the authors agree for publication.

Ethics approval and consent to participate

Ethics approval was obtained from ethics committee of the second Hospital of Hebei Medical University. Informed consent was obtained on admission.

Funding

Not applicable.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Cardiology, The Second Hospital of Hebei Medical University, No. 215 Hepingxi Road, Xinhua District, Shijiazhuang, 050005, Hebei, China

References

  1. Gouveia V, Oliveira DC, Tenorio E, Brito N, Sarinho E. Percutaneous coronary intervention: safety of methotrexate and its possible benefits on restenosis after bare-metal stent deployment. Cardiol Res. 2016;7:104–9.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Esfandi A, Fotouhi M, Allami A, Ebrahimi M. Comparison between the outcomes of intracoronary and intravenous administration of eptifibatide during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction. J Atheroscler Thromb. 2016;23:465–76.View ArticlePubMedGoogle Scholar
  3. Dilic M, Terzic I, Kulic M. Primary percutaneous coronary intervention network in Bosnia and Herzegovina: where are we now and how to improve PCI network. Int J Cardiol. 2016;217(Suppl):S49–51.View ArticlePubMedGoogle Scholar
  4. Shuvy M, Qiu F, Chee ATA, Graham JJ, Abuzeid W, Buller C, Strauss BH, Wijeysundera HC. Management of chronic total coronary occlusion in stable ischemic heart disease by percutaneous coronary intervention versus coronary artery bypass grafting versus medical therapy. Am J Cardiol. 2017;120:759–64.View ArticlePubMedGoogle Scholar
  5. Shoukat S, Gowani SA, Jafferani A, Dhakam SH. Contrast-induced nephropathy in patients undergoing percutaneous coronary intervention. Cardiol Res Pract. 2010. https://doi.org/10.4061/2010/649164.PubMedPubMed CentralView ArticleGoogle Scholar
  6. Li W, Yu Y, He H, Chen J, Zhang D. Urinary kidney injury molecule-1 as an early indicator to predict contrast-induced acute kidney injury in patients with diabetes mellitus undergoing percutaneous coronary intervention. Biomed Rep. 2015;3:509–12.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Xing Y, Wei RB, Tang L, Yang Y, Zheng XY, Wang ZC, Gao YW. Protective effect of salidroside on contrast-induced nephropathy in comparison with N-acetylcysteine and its underlying mechanism. Chin J Integr Med. 2015;21:266–73.View ArticlePubMedGoogle Scholar
  8. Yao L, Kolluru GK, Kevil CG, Zhang WW. Intravascular radiocontrast iodixanol increases permeability of proximal tubule epithelium: a possible mechanism of contrast-induced nephropathy. Vasc Endovascular Surg. 2013;47:632–8.View ArticlePubMedGoogle Scholar
  9. Bei W, Li H, Lin K, Wang K, Chen S, Guo X, Liu Y, Tan N, Chen J, Investigators T. Post-Hoc study: intravenous hydration treatment in chinese patients with high risk of contrast-induced nephropathy following percutaneous coronary intervention. Sci Rep. 2017;7:45023.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Assadi F. Acetazolamide for prevention of contrast-induced nephropathy: a new use for an old drug. Pediatr Cardiol. 2006;27:238–42.View ArticlePubMedGoogle Scholar
  11. Wu YW, Leow KS, Zhu Y, Tan CH. Prevention and management of adverse reactions induced by iodinated contrast media. Ann Acad Med Singapore. 2016;45:157–64.PubMedGoogle Scholar
  12. Yang D, Yang D, Jia R, Ding G. Selective inhibition of the reverse mode of Na(+)/Ca(2+) exchanger attenuates contrast-induced cell injury. Am J Nephrol. 2013;37:264–73.View ArticlePubMedGoogle Scholar
  13. Huynh K, Kiriazis H, Du XJ, Love JE, Jandeleit-Dahm KA, Forbes JM, McMullen JR, Ritchie RH. Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes. Diabetologia. 2012;55:1544–53.View ArticlePubMedGoogle Scholar
  14. McCarthy CP, Mullins KV, Kerins DM. The role of trimetazidine in cardiovascular disease: beyond an anti-anginal agent. Eur Heart J Cardiovasc Pharmacother. 2016;2:266–72.View ArticlePubMedGoogle Scholar
  15. Wang XL, Zhang T, Hu LH, Sun SQ, Zhang WF, Sun Z, Shen LH, He B. Comparison of effects of different statins on contrast-induced acute kidney injury in rats: histopathological and biochemical findings. Oxid Med Cell Longev. 2017;2017:6282486.PubMedPubMed CentralGoogle Scholar
  16. Aubry P, Brillet G, Catella L, Schmidt A, Benard S. Outcomes, risk factors and health burden of contrast-induced acute kidney injury: an observational study of one million hospitalizations with image-guided cardiovascular procedures. BMC Nephrol. 2016;17:167.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Chronopoulos A, Cruz DN, Ronco C. Hospital-acquired acute kidney injury in the elderly. Nat Rev Nephrol. 2010;6:141–9.View ArticlePubMedGoogle Scholar
  18. Sarabu N, Rahman M. Nephrology update: acute kidney injury. FP Essent. 2016;444:11–7.PubMedGoogle Scholar
  19. Luders F, Meyborg M, Malyar N, Reinecke H. The preinterventional cystatin-creatinine-ratio: a prognostic marker for contrast medium-induced acute kidney injury and long-term all-cause mortality. Nephron. 2015;131:59–65.View ArticlePubMedGoogle Scholar
  20. Caiazza A, Russo L, Sabbatini M, Russo D. Hemodynamic and tubular changes induced by contrast media. Biomed Res Int. 2014;2014:578974.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Oudemans-van Straaten HM. Contrast nephropathy, pathophysiology and prevention. Int J Artif Organs. 2004;27:1054–65.View ArticlePubMedGoogle Scholar
  22. Yang DW, Yang DP, Jia RH, Lin S. Effects of selective inhibition of reverse mode of Na(+)/Ca(2+) exchanger on rats with contrast-induced acute kidney injury. Zhonghua Yi Xue Za Zhi. 2013;93:1750–4.PubMedGoogle Scholar
  23. Indo HP, Yen HC, Nakanishi I, Matsumoto K, Tamura M, Nagano Y, Matsui H, Gusev O, Cornette R, Okuda T, Minamiyama Y, Ichikawa H, Suenaga S, Oki M, Sato T, Ozawa T, Clair DK, Majima HJ. A mitochondrial superoxide theory for oxidative stress diseases and aging. J Clin Biochem Nutr. 2015;56:1–7.View ArticlePubMedGoogle Scholar
  24. Balta S, Demirkol S, Celik T. Coenzyme Q10 supplementation may improve diastolic heart functions especially coronary artery disease patients. Hemodial Int. 2013;17:467–8.View ArticlePubMedGoogle Scholar
  25. Liu Z, Chen JM, Huang H, Kuznicki M, Zheng S, Sun W, Quan N, Wang L, Yang H, Guo HM, Li J, Zhuang J, Zhu P. The protective effect of trimetazidine on myocardial ischemia/reperfusion injury through activating AMPK and ERK signaling pathway. Metabolism. 2016;65:122–30.View ArticlePubMedGoogle Scholar
  26. Gong X, Fan G, Wang W, Wang G. Trimetazidine protects umbilical cord mesenchymal stem cells against hypoxia and serum deprivation induced apoptosis by activation of Akt. Cell Physiol Biochem. 2014;34:2245–55.View ArticlePubMedGoogle Scholar
  27. Costa LM, Rezende PC, Garcia RM, Uchida AH, Seguro LF, Scudeler TL, Bocchi EA, Krieger JE, Hueb W, Ramires JA, Filho RK. Role of trimetazidine in ischemic preconditioning in patients with symptomatic coronary artery disease. Medicine (Baltimore). 2015;94:e1161.View ArticleGoogle Scholar
  28. Ambrosio G, Tamargo J, Grant PJ. Non-haemodynamic anti-anginal agents in the management of patients with stable coronary artery disease and diabetes: a review of the evidence. Diab Vasc Dis Res. 2016;13:98–112.View ArticlePubMedGoogle Scholar
  29. Onbasili AO, Yeniceriglu Y, Agaoglu P, Karul A, Tekten T, Akar H, Discigil G. Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures. Heart. 2007;93:698–702.View ArticlePubMedGoogle Scholar
  30. Shehata M. Impact of trimetazidine on incidence of myocardial injury and contrast-induced nephropathy in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention. Am J Cardiol. 2014;114:389–94.View ArticlePubMedGoogle Scholar
  31. Tsai KL, Huang YH, Kao CL, Yang DM, Lee HC, Chou HY, Chen YC, Chiou GY, Chen LH, Yang YP, Chiu TH, Tsai CS, Ou HC, Chiou SH. A novel mechanism of coenzyme Q10 protects against human endothelial cells from oxidative stress-induced injury by modulating NO-related pathways. J Nutr Biochem. 2012;23:458–68.View ArticlePubMedGoogle Scholar
  32. Wu Q, Qi B, Liu Y, Cheng B, Liu L, Li Y, Wang Q. Mechanisms underlying protective effects of trimetazidine on endothelial progenitor cells biological functions against H2O2-induced injury: involvement of antioxidation and Akt/eNOS signaling pathways. Eur J Pharmacol. 2013;707:87–94.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s) 2018

Advertisement